42,068 Shares in Encompass Health Co. (NYSE:EHC) Acquired by Trexquant Investment LP

Trexquant Investment LP acquired a new stake in Encompass Health Co. (NYSE:EHC) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 42,068 shares of the company’s stock, valued at approximately $3,885,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Vanguard Group Inc. raised its stake in Encompass Health by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 10,404,081 shares of the company’s stock valued at $960,817,000 after buying an additional 138,196 shares in the last quarter. State Street Corp raised its position in shares of Encompass Health by 0.7% during the 3rd quarter. State Street Corp now owns 3,025,769 shares of the company’s stock worth $292,410,000 after acquiring an additional 21,329 shares in the last quarter. Alliancebernstein L.P. lifted its stake in Encompass Health by 6.0% during the fourth quarter. Alliancebernstein L.P. now owns 2,076,869 shares of the company’s stock worth $191,799,000 after purchasing an additional 117,617 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Encompass Health by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 1,679,774 shares of the company’s stock valued at $155,176,000 after purchasing an additional 6,164 shares in the last quarter. Finally, Copeland Capital Management LLC increased its stake in Encompass Health by 0.7% in the fourth quarter. Copeland Capital Management LLC now owns 1,293,098 shares of the company’s stock valued at $119,418,000 after purchasing an additional 8,548 shares during the last quarter. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Encompass Health

In other news, CAO Andrew L. Price sold 5,042 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $98.29, for a total transaction of $495,578.18. Following the sale, the chief accounting officer now owns 69,164 shares of the company’s stock, valued at $6,798,129.56. The trade was a 6.79 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 2.10% of the company’s stock.

Encompass Health Stock Performance

NYSE:EHC opened at $98.14 on Friday. The firm has a market cap of $9.88 billion, a price-to-earnings ratio of 22.00, a price-to-earnings-growth ratio of 2.31 and a beta of 0.87. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.05 and a quick ratio of 1.04. Encompass Health Co. has a 1-year low of $78.53 and a 1-year high of $104.55. The firm’s fifty day moving average price is $99.25 and its 200 day moving average price is $97.71.

Encompass Health (NYSE:EHC) last issued its quarterly earnings results on Thursday, February 6th. The company reported $1.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.12. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. On average, sell-side analysts expect that Encompass Health Co. will post 4.8 EPS for the current year.

Encompass Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Tuesday, April 1st will be issued a $0.17 dividend. The ex-dividend date of this dividend is Tuesday, April 1st. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.69%. Encompass Health’s dividend payout ratio is presently 15.25%.

Analysts Set New Price Targets

EHC has been the subject of several recent analyst reports. Barclays boosted their price objective on shares of Encompass Health from $116.00 to $118.00 and gave the stock an “overweight” rating in a research report on Friday, February 7th. StockNews.com lowered Encompass Health from a “buy” rating to a “hold” rating in a report on Thursday. Royal Bank of Canada reissued an “outperform” rating and issued a $110.00 target price on shares of Encompass Health in a report on Tuesday, February 11th. William Blair reissued an “outperform” rating on shares of Encompass Health in a research report on Friday, February 7th. Finally, KeyCorp boosted their price objective on Encompass Health from $117.00 to $120.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. One analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $107.67.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.